LPOXY Therapeutics to Acquire Key Assets from Xeno Biosciences to Advance C. difficile Infection Prevention Therapy

LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced...

January 06, 2025 | Monday | News
Hanx Biopharmaceuticals Doses First Patient in Australia for Phase 1 Clinical Trial of Groundbreaking Cancer Therapy HX044

Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical...

January 03, 2025 | Friday | News
Genesis Medtech Launches iReach Omnia, World’s First Powered Stapler with 90° Articulation, in China

Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for marke...

January 02, 2025 | Thursday | News
CARsgen Therapeutics Launches Investigator-Initiated Trial in China for KJ-C2219, an Allogeneic CAR T-Cell Therapy Targeting CD19/CD20

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

January 01, 2025 | Wednesday | News
Takeda Receives Japanese Regulatory Approval for HYQVIA® in Primary and Secondary Immunodeficiency Disorders

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...

December 31, 2024 | Tuesday | News
Sanofi and SK bioscience Expand Collaboration to Develop Next-Generation Pneumococcal Vaccines for Global Impact

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and...

December 24, 2024 | Tuesday | News
FDA Approves ALYFTREK® (Vanzacaftor/Tezacaftor/Deutivacaftor) as Once-Daily Treatment for Cystic Fibrosis

 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (v...

December 21, 2024 | Saturday | News
MSD and Hansoh Pharma Enter Exclusive Global License Agreement for Investigational GLP-1 Receptor Agonist HS-10535

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company,  announced that they ...

December 19, 2024 | Thursday | News
Roche Secures CE Mark for cobas® Mass Spec Solution, Bringing Automated Clinical Mass Spectrometry to Routine Laboratories Worldwide

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 ana...

December 19, 2024 | Thursday | News
Sanofi and Teva’s Duvakitug Achieves Key Milestones in Phase 2b Study for Ulcerative Colitis and Crohn’s Disease

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endp...

December 18, 2024 | Wednesday | News
Merck’s WELIREG® Receives Positive CHMP Opinion for VHL Disease-Associated Tumors and Advanced RCC in the EU

Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...

December 16, 2024 | Monday | News
Roche Announces European Approval of Vabysmo® Prefilled Syringe for Treatment of Major Retinal Diseases

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe ...

December 16, 2024 | Monday | News
BeiGene Unveils Promising Early Data on CDK Inhibitors at SABCS, Paving the Way for Next-Generation Breast Cancer Treatments

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., shared new data ...

December 13, 2024 | Friday | News
A2A Pharmaceuticals Advances Phase 1 Clinical Trial of TACC3 Inhibitor A0-252 in Ovarian, TNBC, and Endometrial Cancers

A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...

December 13, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close